Tesi’s portfolio company: Aurealis Therapeutics AG - tesi.fi

Suomeksi

Search for

For companies
For investors
Investments
- Investments
- Companies
- Funds
- Cases
Team
News
Market data
Sustainability
About Tesi

HomeCompaniesAurealis Therapeutics AG

aurealistherapeutics.com

Portfolio
Venture Capital Investments

Industry
Health & Life Science

Manager
Kalle Åström

Investment Year
2021

Aurealis Therapeutics develops curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with their four-in-one biologic drug, AUP-16.

Subscribe

* indicates required

Email Address *

First Name

Last Name

How often would you like to hear from us? *

Daily, if there is new content
Once a week
Once a month

Marketing Permissions *

Accept

By accepting this form, you give Tesi and the partners who produce its newsletter permission to process your information with the newsletters. You can unsubscribe at any time by clicking the link in the footer of our emails or by contacting info@tesi.fi For information about our privacy practices, please visit our website https://www.tesi.fi/en/privacy-policy/.

Grow Together.

Tesi (Finnish Industry Investment Ltd)
Porkkalankatu 1, 00180 Helsinki